肿瘤细胞治疗研究
英文原题：Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties.
Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties.
过去十年间，针对 B 细胞恶性肿瘤患者的 CAR-T 细胞治疗已从一项实验性技术发展为临床可行的选择。
过去十年，针对B细胞恶性肿瘤患者的CAR-T细胞疗法已从实验技术发展为临床可行的治疗选择。目前，美国食品药品监督管理局（FDA）已批准4种靶向B细胞表面标志物CD19的CAR-T细胞产品。尽管复发/难治性（r/r）急性淋巴细胞白血病（ALL）和非霍奇金淋巴瘤（NHL）患者的完全缓解率令人瞩目，仍有相当比例患者复发，且肿瘤常呈CD19低表达或阴性表型。为此，研究者提出将CD20等其他B细胞表面分子作为CAR-T靶点。本研究并列比较了靶向CD20的CAR-T细胞活性，这些细胞的抗原识别模块分别来源于小鼠抗体1F5和Leu16，以及人抗体2F2。与CD19特异性CAR-T细胞相比，CD20特异性CAR-T细胞的亚群组成和细胞因子分泌存在差异，但其体外和体内效力相近。
Over the past decade, CAR T cell therapy for patients with B cell malignancies has evolved from an experimental technique to a clinically feasible option. To date, four CAR T cell products specific for a B cell surface marker, CD19, have been approved by the FDA. Despite the spectacular rates of complete remission in r/r ALL and NHL patients, a significant proportion of patients still relapse, frequently with the CD19 low/negative tumor phenotype. To address this issue, additional B cell surface molecules such as CD20 were proposed as targets for CAR T cells. Here, we performed a side-by-side comparison of the activity of CD20-specific CAR T cells based on the antigen-recognition modules derived from the murine antibodies, 1F5 and Leu16, and from the human antibody, 2F2. Whereas CD20-specific CAR T cells differed from CD19-specific CAR T cells in terms of subpopulation composition and cytokine secretion, they displayed similar in vitro and in vivo potency.
MEMBER ACCOUNT
登录成功会直接打开下一页。
